Table 22-7.
Commercial | Medicare | Medicaid | |
---|---|---|---|
AMI | |||
β-Blocker persistence* | 81.3 | 87.3 | 80.5 |
Cholesterol management for patients with CVD | |||
Cholesterol screening | 88.1 | 88.8 | 82.0 |
LDL cholesterol control (<100 mg/dL) | 59.8 | 56.5 | 42.1 |
Hypertension | |||
BP <140/90 mm Hg | 65.4 | 64.0 | 56.8 |
DM | |||
HbA1c testing | 90.0 | 91 | 82.5 |
HbA1c >9.0% | 28.3 | 26.5 | 43.0 |
Eye examination performed | 56.9 | 66.0 | 53.3 |
LDL cholesterol screening | 85.3 | 88.3 | 75.0 |
LDL cholesterol <100 mg/dL | 48.1 | 52.5 | 35.2 |
Monitoring nephropathy | 83.8 | 89.9 | 77.8 |
BP <140/90 mm Hg | 65.8 | 63.1 | 60.9 |
Advising smokers and tobacco users to quit | 77.6 | 81.5 | 74.6 |
BMI percentile assessment in children and adolescents | 44.7 | N/A | 46 |
Nutrition counseling (children and adolescents) | 46.4 | N/A | 50.1 |
Counseling for physical activity (children and adolescents) | 43.0 | N/A | 40.6 |
BMI assessment for adults | 55.4 | 68.2 | 52.6 |
Physical activity discussion in older adults (≥65 y of age) | N/A | 53.0 | N/A |
Physical activity advice in older adults (≥65 y of age) | N/A | 48.7 | N/A |
Values are percentages.
AMI indicates acute myocardial infarction; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DM, diabetes mellitus; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; and N/A, not available or not applicable.
β-Blocker persistence: Received persistent β-blocker treatment for 6 mo after AMI hospital discharge.